Analysis
Sep 18, 2026•1 min read
Mirae Asset Report Shows Korean Pharma & Bio Firms Strengthening Fundamentals Amid Market Weakness
Despite short‑term stock pressure from interest rates and supply issues, Korean pharma and biotech companies are pursuing M&A, tech exports and capacity investments, boosting fundamentals, says a Mirae Asset report.
Analysis
Sep 13, 2026•1 min read
Samsung Biologics offers CHF 44.31 per share to acquire PolyPeptide Group
Samsung Biologics proposes a CHF 44.31 per share price, about 40% above PolyPeptide’s April 10 close, valuing the deal at CHF 1.46 bn.
Analysis
Sep 13, 2026•1 min read
Teva to Acquire BioXcel Therapeutics' Neuroscience Assets for Up to $125M
Teva Pharmaceuticals plans to buy BioXcel Therapeutics' neuroscience portfolio for $57.5M upfront with up to $67.5M in milestones as BioXcel navigates Chapter 11 bankruptcy.
Analysis
Aug 30, 2026•1 min read
Vertex Pharmaceuticals to Acquire Crinetics for $10B, Securing Palsonify and CAH Candidate
Vertex Pharma announced a $10 billion acquisition of Crinetics, adding the potential blockbuster Palsonify and ACTH‑receptor antagonist atumelnant for congenital adrenal hyperplasia.
Analysis
Aug 27, 2026•1 min read
Klick Health Acquires Oxford PharmaGenesis in Third Takeover Within 18 Months
Klick Health completes its third acquisition in 18 months, buying Oxford PharmaGenesis to expand globally and deepen scientific expertise.
Analysis
Aug 26, 2026•1 min read
Kimball Electronics Pursues M&A to Expand Life‑Science CDMO Footprint in Europe and India
Kimball Electronics announced plans to grow its life‑science contract manufacturing capabilities through acquisitions in Europe and India.
1
Analysis
Aug 25, 2026•1 min read
Pfizer’s $10.5B Oncology Deal with Innovent Completed in Under Five Months
Pfizer finalized a $10.5 billion, 12‑drug oncology partnership with Innovent Biologics in less than five months, despite facing internal stress tests.